{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T19:30:17Z","timestamp":1789587017259,"version":"build-2803163510"},"reference-count":30,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk A\/S","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Diabetes & Endocrinology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/s2213-8587(26)00125-7","type":"journal-article","created":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T21:34:06Z","timestamp":1780868046000},"page":"662-677","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Cagrilintide\u2013semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study"],"prefix":"10.1016","volume":"14","author":[{"given":"John B","family":"Buse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harpreet S","family":"Bajaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stine-Mathilde","family":"Dalskov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucienne","family":"Donaldson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helene H","family":"Hansen Duus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Therese Wilbek","family":"Fabricius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Haluz\u00edk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ildiko","family":"Lingvay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue D","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard E","family":"Pratley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshay B","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl 1","key":"10.1016\/S2213-8587(26)00125-7_bib2","first-page":"S27","article-title":"2. Diagnosis and classification of diabetes: standards of care in diabetes\u20142026","volume":"49","author":"Bajaj","year":"2026","journal-title":"Diabetes Care"},{"key":"10.1016\/S2213-8587(26)00125-7_bib3","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/S2213-8587(26)00125-7_bib4","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.2337\/dci22-0034","article-title":"Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"45","author":"Davies","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/S2213-8587(26)00125-7_bib7","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1111\/dom.12932","article-title":"Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity","volume":"19","author":"Blundell","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/S2213-8587(26)00125-7_bib8","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1124\/pr.115.010629","article-title":"Amylin: pharmacology, physiology, and clinical potential","volume":"67","author":"Hay","year":"2015","journal-title":"Pharmacol Rev"},{"key":"10.1016\/S2213-8587(26)00125-7_bib9","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S1054-3589(05)52008-8","article-title":"Inhibition of glucagon secretion","volume":"52","author":"Young","year":"2005","journal-title":"Adv Pharmacol"},{"key":"10.1016\/S2213-8587(26)00125-7_bib10","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s42255-026-01465-4","article-title":"The story of amylin: from physiology to therapy","volume":"8","author":"Secher","year":"2026","journal-title":"Nat Metab"},{"key":"10.1016\/S2213-8587(26)00125-7_bib11","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1124\/jpet.121.000567","article-title":"AM833 is a novel agonist of calcitonin family G protein-coupled receptors: pharmacological comparison with six selective and nonselective agonists","volume":"377","author":"Fletcher","year":"2021","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/S2213-8587(26)00125-7_bib12","doi-asserted-by":"crossref","first-page":"11183","DOI":"10.1021\/acs.jmedchem.1c00565","article-title":"Development of cagrilintide: a long-acting amylin analogue","volume":"64","author":"Kruse","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/S2213-8587(26)00125-7_bib13","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/CRD.0000000000000513","article-title":"Cagrilintide: a long-acting amylin analog for the treatment of obesity","volume":"32","author":"D'Ascanio","year":"2024","journal-title":"Cardiol Rev"},{"key":"10.1016\/S2213-8587(26)00125-7_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-8587(26)00126-9","article-title":"Efficacy and safety of once-weekly cagrilintide\u2013semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study","author":"Aroda","year":"2026","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/S2213-8587(26)00125-7_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(26)01022-6","article-title":"Cagrilintide\u2013semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study","author":"Rosenstock","year":"2026","journal-title":"Lancet"},{"issue":"suppl 1","key":"10.1016\/S2213-8587(26)00125-7_bib16","first-page":"1","article-title":"Assessing cardiovascular safety and outcomes with the combination of cagrilintide and semaglutide (CagriSema): REDEFINE 3 randomised clinical trial baseline characteristics and methods","volume":"19","author":"Cavender","year":"2026","journal-title":"Obes Facts"},{"key":"10.1016\/S2213-8587(26)00125-7_bib17","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1056\/NEJMoa2502082","article-title":"Cagrilintide\u2013semaglutide in adults with overweight or obesity and type 2 diabetes","volume":"393","author":"Davies","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/S2213-8587(26)00125-7_bib18","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1056\/NEJMoa2502081","article-title":"Coadministered cagrilintide and semaglutide in adults with overweight or obesity","volume":"393","author":"Garvey","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/S2213-8587(26)00125-7_bib19","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S2213-8587(25)00402-4","article-title":"Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5: a mutlicentre, randomised, active-controlled, phase 3a trial","volume":"14","author":"Yamauchi","year":"2026","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/S2213-8587(26)00125-7_bib20","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/S2213-8587(26)00125-7_bib22","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1002\/bimj.201000239","article-title":"Graphical approaches for multiple comparison procedures using weighted Bonferroni, Simes, or parametric tests","volume":"53","author":"Bretz","year":"2011","journal-title":"Biom J"},{"key":"10.1016\/S2213-8587(26)00125-7_bib23","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/s41366-020-00733-x","article-title":"Estimating and reporting treatment effects in clinical trials for weight management: using estimands to interpret effects of intercurrent events and missing data","volume":"45","author":"Wharton","year":"2021","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/S2213-8587(26)00125-7_bib24","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1111\/dom.13804","article-title":"Incorporating and interpreting regulatory guidance on estimands in diabetes clinical trials: the PIONEER 1 randomized clinical trial as an example","volume":"21","author":"Aroda","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/S2213-8587(26)00125-7_bib25","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/S0140-6736(23)01163-7","article-title":"Efficacy and safety of co-administered once-weekly cagrilintide 2\u00b74 mg with once-weekly semaglutide 2\u00b74 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial","volume":"402","author":"Frias","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/S2213-8587(26)00125-7_bib26","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0140-6736(21)01443-4","article-title":"Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial","volume":"398","author":"Ludvik","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/S2213-8587(26)00125-7_bib27","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/S0140-6736(21)00845-X","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2\u00b74 mg for weight management: a randomised, controlled, phase 1b trial","volume":"397","author":"Enebo","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/S2213-8587(26)00125-7_bib28","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1111\/dom.14280","article-title":"The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity","volume":"23","author":"Friedrichsen","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"suppl 1","key":"10.1016\/S2213-8587(26)00125-7_bib29","first-page":"S166","article-title":"8. Obesity and weight management for the prevention and treatment of diabetes: standards of care in diabetes\u20132026","volume":"49","author":"Bajaj","year":"2026","journal-title":"Diabetes Care"},{"key":"10.1016\/S2213-8587(26)00125-7_bib30","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/S0140-6736(21)01919-X","article-title":"Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation","volume":"399","author":"Lingvay","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/S2213-8587(26)00125-7_bib31","doi-asserted-by":"crossref","first-page":"E797","DOI":"10.1503\/cmaj.250502","article-title":"Pharmacotherapy for obesity management in adults: 2025 clinical practice guideline update","volume":"197","author":"Pedersen","year":"2025","journal-title":"CMAJ"},{"key":"10.1016\/S2213-8587(26)00125-7_bib32","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2\u00b74 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/S2213-8587(26)00125-7_bib33","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1185\/030079908X253537","article-title":"Effect of pramlintide as an adjunct to basal insulin on markers of cardiovascular risk in patients with type 2 diabetes","volume":"24","author":"Wysham","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/S2213-8587(26)00125-7_bib34","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1016\/S0140-6736(21)01751-7","article-title":"Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial","volume":"398","author":"Lau","year":"2021","journal-title":"Lancet"}],"updated-by":[{"DOI":"10.1016\/s2213-8587(26)00157-9","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000}},{"DOI":"10.1016\/s2213-8587(26)00157-9","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000}}],"container-title":["The Lancet Diabetes & Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213858726001257?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213858726001257?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:07:10Z","timestamp":1785974830000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213858726001257"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2213858726001257"],"URL":"https:\/\/doi.org\/10.1016\/s2213-8587(26)00125-7","relation":{},"ISSN":["2213-8587"],"issn-type":[{"value":"2213-8587","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cagrilintide\u2013semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study","name":"articletitle","label":"Article Title"},{"value":"The Lancet Diabetes & Endocrinology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/S2213-8587(26)00125-7","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/S2213-8587(26)00129-4","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}